Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5

Among patients with relapsed/refractory DLBCL, subcutaneous epcoritamab combined with lenalidomide showed promising antitumor activity with a tolerable safety profile, according to data from the phase 1b/2 EPCORE NHL-5 trial presented during the 2023 American Society of Hematology Annual Meeting. Median duration of epcoritamab exposure was 3.8 months (range, 0-7.5) and median duration of lenalidomide exposure was 4.0 months (range, 0.1-8.2); 15 patients (58%) remain on epcoritamab and lenalidomide. The most common grade 3-4 treatment-emergent adverse events were neutropenia (58%), anemia (15%), thrombocytopenia (15%), and febrile neutropenia (12%).